Sputum microRNA Biomarkers for Identifying Lung Cancer in Indeterminate Solitary Pulmonary Nodules

Purpose: The early detection of lung cancer in heavy smokers by low-dose CT (LDCT) can reduce the mortality. However, LDCT screening increases the number of indeterminate solitary pulmonary nodules (SPN) in asymptomatic individuals, leading to overdiagnosis. Making a definitive preoperative diagnosis of malignant SPNs has been a clinical challenge. We have demonstrated that sputum miRNAs could provide potential biomarkers for lung cancer. Here, we aimed to develop sputum miRNA biomarkers for diagnosis of malignant SPNs. Experimental Design: Using quantitative RT-PCR, we evaluated expressions of 13 sputum miRNAs, previously identified sputum miRNA signatures of lung cancer, in a training set of 122 patients with either malignant (n = 60) or benign SPNs (n = 62) to define a panel of biomarkers. We then validated the biomarker panel in an internal testing set of 136 patients with either malignant (n = 67) or benign SPNs (n = 69), and an external testing cohort of 155 patients with either malignant (n = 76) or benign SPNs (n = 79). Results: In the training set, a panel of three miRNA biomarkers (miRs21, 31, and 210) was developed, producing 82.93% sensitivity and 87.84% specificity for identifying malignant SPNs. The sensitivity and specificity of the biomarkers in the two independent testing cohorts were 82.09% and 88.41%, 80.52% and 86.08%, respectively, confirming the diagnostic value. Conclusions: Sputum miRNA biomarkers may improve LDCT screening for lung cancer in heavy smokers by preoperatively diagnosing malignant SPNs. Nevertheless, a prospective study in a large population to validate the biomarkers is needed. Clin Cancer Res; 21(2); 484–9. ©2015 AACR.

[1]  F. Jiang,et al.  Evaluation of lung flute in sputum samples for molecular analysis of lung cancer , 2013, Clinical and Translational Medicine.

[2]  Feng Jiang,et al.  Analysis of MicroRNAs in Sputum to Improve Computed Tomography for Lung Cancer Diagnosis , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Zhenqiu Liu,et al.  Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis , 2008, Cancer.

[4]  Sunita Ghosh,et al.  Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. , 2012, Clinical and investigative medicine. Medecine clinique et experimentale.

[5]  F. Jiang,et al.  Identification of ENO1 as a potential sputum biomarker for early-stage lung cancer by shotgun proteomics. , 2014, Clinical lung cancer.

[6]  O. Auerbach,et al.  Cancer of the lung: the cytology of sputum prior to the development of carcinoma. , 1965, Acta cytologica.

[7]  Feng Jiang,et al.  Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers , 2010, International journal of cancer.

[8]  T. Byers,et al.  Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. , 2004, Cancer Detection and Prevention.

[9]  B. Kramer,et al.  Overdiagnosis in low-dose computed tomography screening for lung cancer. , 2014, JAMA internal medicine.

[10]  Feng Jiang,et al.  Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[11]  E. Thunnissen,et al.  Molecular sputum analysis for the diagnosis of lung cancer , 2013, British Journal of Cancer.

[12]  J. Herman,et al.  Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. , 2006, Cancer research.

[13]  Y. Miller,et al.  Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. , 2003, The Journal of molecular diagnostics : JMD.

[14]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[15]  Hong-Bin Fang,et al.  Genetic Deletions in Sputum as Diagnostic Markers for Early Detection of Stage I Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[16]  Hong Peng,et al.  Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. , 2010, Lung cancer.

[17]  C. Croce,et al.  miRNAs, Cancer, and Stem Cell Division , 2005, Cell.

[18]  Zhenqiu Liu,et al.  Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. , 2009, Lung cancer.

[19]  F. Jiang,et al.  A Panel of Sputum-Based Genomic Marker for Early Detection of Lung Cancer , 2010, Cancer Prevention Research.

[20]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[21]  J. Austin,et al.  Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. , 2005, Radiology.

[22]  J. Herman,et al.  Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. , 2006, Cancer research.

[23]  F. Jiang,et al.  Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers , 2010, Modern Pathology.

[24]  Michael F. Ochs,et al.  Serum microRNA Biomarkers for Detection of Non-Small Cell Lung Cancer , 2012, PloS one.

[25]  M. Zhan,et al.  Characterization of microRNA transcriptome in lung cancer by next‐generation deep sequencing , 2014, Molecular oncology.

[26]  M. Spitz,et al.  Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer , 2008, Modern Pathology.

[27]  E. Wiemer,et al.  miRNAs and cancer , 2006, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.